Exhibit 99.1 Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities Clinical Pipeline Update: In October 2026, the Company initiated EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel- group, Phase 2b study evaluating mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 a ...